Number of items: 6.
2021
Brown, J. W. L. et al.
(2021)
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
Lancet Neurology, 20(9),
pp. 709-720.
(doi: 10.1016/S1474-4422(21)00179-4)
York, E. N. et al.
(2021)
MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis.
Brain Communications, 3(4),
fcab249.
(doi: 10.1093/braincomms/fcab249)
(PMID:34877533)
(PMCID:PMC8643503)
2017
Davidson, Amy I., Halstead, Susan K., Goodfellow, John A., Chavada, Govind, Mallik, Arup, Overell, James, Lunn, Michael P., McConnachie, Alex
ORCID: https://orcid.org/0000-0002-7262-7000, van Doorn, Pieter and Willison, Hugh J.
ORCID: https://orcid.org/0000-0002-5997-1683
(2017)
Inhibition of complement in Guillain-Barré Syndrome: the ICA-GBS study.
Journal of the Peripheral Nervous System, 6,
pp. 4-12.
(doi: 10.1111/jns.12194)
(PMID:27801990)
2016
Kavanagh, D. et al.
(2016)
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.
Blood, 128(24),
pp. 2824-2833.
(doi: 10.1182/blood-2016-05-715987)
(PMID:27663672)
2011
Fitzpatrick, A.M., Mann, C.A., Barry, S.
ORCID: https://orcid.org/0000-0003-3039-8729, Brennan, K., Overell, J.R. and Willison, H.J.
ORCID: https://orcid.org/0000-0002-5997-1683
(2011)
An open label clinical trial of complement inhibition in multifocal motor neuropathy.
Journal of the Peripheral Nervous System, 16(2),
pp. 84-91.
(doi: 10.1111/j.1529-8027.2011.00328.x)
2007
Overell, J.R., Hsieh, S.-T., Odaka, M., Yuki, N. and Willison, H.J.
ORCID: https://orcid.org/0000-0002-5997-1683
(2007)
Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders.
Cochrane Database of Systematic Reviews(1),
CD004761.
(doi: 10.1002/14651858.CD004761.pub2)
This list was generated on Tue Jul 1 10:59:40 2025 BST.